Pei Gaiqin, Chen Li, Wang Yang, He Chengqi, Fu Chenying, Wei Quan
Department of Rehabilitation Medicine and Institute of Rehabilitation Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Key Laboratory of Rehabilitation Medicine in Sichuan Province, Chengdu, Sichuan, China.
Front Cell Dev Biol. 2023 May 9;11:1181515. doi: 10.3389/fcell.2023.1181515. eCollection 2023.
The treatment of cardiovascular and cerebrovascular diseases have undergone major advances in recent decades, allowing for a more effective prevention of cardiovascular and cerebrovascular events. However, cardiac and cerebral atherothrombotic complications still account for substantial morbidity and mortality worldwide. Novel therapeutic strategies are critical to improve patient outcomes following cardiovascular diseases. miRNAs are small non-coding RNAs, that regulate gene expression. Here, we discuss the role of miR-182 in regulating myocardial proliferation, migration, hypoxia, ischemia, apoptosis and hypertrophy in atherosclerosis, CAD, MI, I/R injury, organ transplant, cardiac hypertrophy, hypertension, heart failure, congenital heart disease and cardiotoxicity. Besides, we also summarize the current progress of miR-182 therapeutics in clinical development and discuss challenges that will need to be overcome to enter the clinic for patients with cardiac disease.
近几十年来，心血管疾病的治疗取得了重大进展，能够更有效地预防心血管事件。然而，心脏和脑动脉粥样硬化血栓形成并发症在全球范围内仍然导致大量发病和死亡。新型治疗策略对于改善心血管疾病患者的预后至关重要。微小RNA（miRNA）是一类小的非编码RNA，可调节基因表达。在此，我们讨论miR-182在动脉粥样硬化、冠心病、心肌梗死、缺血/再灌注损伤、器官移植、心脏肥大、高血压、心力衰竭、先天性心脏病和心脏毒性中调节心肌增殖、迁移、缺氧、缺血、凋亡和肥大的作用。此外，我们还总结了miR-182治疗药物在临床开发中的当前进展，并讨论了在进入心脏病患者临床应用时需要克服的挑战。
